Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Parkside Scientific Inc
Profile last edited on: 11/27/2017      CAGE: 6ZSQ6      UEI: P7P9UMUDLEG1

Business Identifier: Readying drug cures for deadly cancers by novel epigenetic approach of turning genes "on/off".
Year Founded
2013
First Award
2016
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

760 Parkside Avenue
Brooklyn, NY 11226
   (212) 289-4018
   N/A
   www.pksci.com
Location: Single
Congr. District: 09
County: Kings

Public Profile

Parkside Scientific Inc. is a preclinical stage drug company focused on designing and developing novel drugs for cancers and inflammatory diseases that work by modulating gene expression. With a strong early patent position and proprietary knowledge of epigenetic control mechanisms of gene transcription, Parkside is pursuing breakthrough platform technology aimed at a variety of intractable cancers and inflammatory diseases.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$824,409
Phase II Dollars
$74,751
Total Awarded
$899,160

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 1 NIH $299,983
Project Title: New Epigenetic Therapy for Multiple Sclerosis
2018 1 NIH $299,641
Project Title: Targeted Epigenetic Therapy for Triple-Negative Breast Cancer
2017 1 NIH $299,536
Project Title: New Th17 Selective Immunomodulators for Inflammatory Disorders

Key People / Management

  Gary Duberstein -- Chief Business Officer & General Counsel

  Qiang Zhang -- Research Director/US

  Ming-Ming Zhou -- Founder and Chief Scientist

Company News

There are no news available.